Investors aiming for above-average returns often turn to the practice of stock picking. Skillful choices in individual stocks can be a catalyst for substantial wealth growth.
Karyopharm Therapeutics Inc (NASDAQ: KPTI) closed the day trading at $5.82 down -1.36% from the previous closing price of $5.9. In other words, the price has decreased by -$1.36 from its previous closing price. On the day, 0.65 million shares were traded. KPTI stock price reached its highest trading level at $6.0934 during the session, while it also had its lowest trading level at $5.52.
On January 19, 2023, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $8.Piper Sandler initiated its Overweight rating on January 19, 2023, with a $8 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Oct 01 ’25 when Abate Kristin sold 362 shares for $6.30 per share. The transaction valued at 2,279 led to the insider holds 10,046 shares of the business.
Paulson Richard A. sold 1,257 shares of KPTI for $8,083 on Sep 15 ’25. The President and CEO now owns 84,046 shares after completing the transaction at $6.43 per share. On Sep 15 ’25, another insider, Mano Michael, who serves as the SVP, General Counsel&Secretary of the company, sold 234 shares for $6.43 each. As a result, the insider received 1,505 and left with 21,425 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, KPTI now has a Market Capitalization of 50466840 and an Enterprise Value of 262886832. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.37. Its current Enterprise Value per Revenue stands at 1.915 whereas that against EBITDA is -2.288.
Stock Price History:
The Beta on a monthly basis for KPTI is 0.36, which has changed by -0.5493612 over the last 52 weeks, in comparison to a change of 0.15822446 over the same period for the S&P500. Over the past 52 weeks, KPTI has reached a high of $16.95, while it has fallen to a 52-week low of $3.51. The 50-Day Moving Average of the stock is -1.37%, while the 200-Day Moving Average is calculated to be -8.43%.
Shares Statistics:
Over the past 3-months, KPTI traded about 218.47K shares per day on average, while over the past 10 days, KPTI traded about 427010 shares per day. A total of 8.65M shares are outstanding, with a floating share count of 7.91M. Insiders hold about 8.81% of the company’s shares, while institutions hold 59.73% stake in the company. Shares short for KPTI as of 1757894400 were 2204008 with a Short Ratio of 10.09, compared to 1755216000 on 2144496. Therefore, it implies a Short% of Shares Outstanding of 2204008 and a Short% of Float of 25.61.
Earnings Estimates
. The current rating of Karyopharm Therapeutics Inc (KPTI) is the result of assessments by 1.0 analysts actively engaged in evaluating its market dynamics.The consensus estimate for the next quarter is -$1.1, with high estimates of -$1.1 and low estimates of -$1.1.
Analysts are recommending an EPS of between -$9.25 and -$9.25 for the fiscal current year, implying an average EPS of -$9.25. EPS for the following year is -$7.52, with 2.0 analysts recommending between -$3.37 and -$11.67.
Revenue Estimates
3 analysts predict $42.25M in revenue for. The current quarter. It ranges from a high estimate of $42.74M to a low estimate of $42M. As of. The current estimate, Karyopharm Therapeutics Inc’s year-ago sales were $38.78MFor the next quarter, 3 analysts are estimating revenue of $38.87M. There is a high estimate of $42.01M for the next quarter, whereas the lowest estimate is $36.5M.
A total of 6 analysts have provided revenue estimates for KPTI’s current fiscal year. The highest revenue estimate was $152.69M, while the lowest revenue estimate was $146.44M, resulting in an average revenue estimate of $149.48M. In the same quarter a year ago, actual revenue was $145.24MBased on 6 analysts’ estimates, the company’s revenue will be $166.02M in the next fiscal year. The high estimate is $188.64M and the low estimate is $155M.
